期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾素抑制剂研究新进展 被引量：1

下载PDF
导出
摘要 近年来大量研究证实，抑制肾素血管紧张素系统（renin angioten sinsystem，RAS）对治疗心血管疾病、肾脏疾病及糖尿病并发症等具有良好的效果。众所周知，经典的RAS通过以下途径激活：血管紧张素原在肾素作用下生成无活性的十肽：血管紧张素Ⅰ，后者经血管紧张素转换酶（ACE）催化形成具有活性的八肽：血管紧张素Ⅱ，
作者 郑敏 刘必成
机构地区 东南大学肾脏病研究所东南大学附属中大医院肾科
出处 《中华高血压杂志》 CAS CSCD 北大核心 2008年第4期297-299,共3页 Chinese Journal of Hypertension
关键词 肾素抑制剂 肾素血管紧张素系统 血管紧张素转换酶 糖尿病并发症 血管紧张素Ⅰ 血管紧张素原 血管紧张素Ⅱ 心血管疾病
分类号 R98 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1[1]Gross F,Lazar J,Orth H.Inhibition of the renin-angiotensinogen reaction by pepstin[J].Science,1971,175:656.
  • 2[2]Cumin F,Evin G,Fehrentz JA,et al.Inhibition of human renin by synthetic peptides derived from its prosegment[J].J Biol Chem,1985,260:9154-9157.
  • 3[3]Wood JM,Gulati N,Forgiarini P,et al.Effects of a specific and long-acting renin inhibitor in the marmoset[J].Hypertension,1985,7:653-658.
  • 4[4]Wood JM,Cumin F,Maibaum J.Pharmacology of renin inhibitors and their application to the treatment of hypertention[J].Pharmacol Ther,1994,61:325-344.
  • 5[5]Maibaum J,Feldman DL.Renin inhibitors as novel treatment for cardiovascular disease[J].Expert Opin Ther Patents,2003,13:589-603.
  • 6[6]Wood JM,Criscione L,de Gasparo M,et al.CGP 38560:orally active,low-molecular-weight renin inhibitor with high potency and specificity[J].J Cardiovasc Pharmacol,1989,14:221-226.
  • 7[7]Lefevre G,Duval M,Poncin A.Direct micro-radioimmunoassay of the new renin inhibitor CGP60536[J].J Immunoassay,2000,21:65-84.
  • 8[8]Rahuel J,Rasetti V,Maibaum J,et al.Structure-based drug design:The discovery of novel nonpeptide orally active inhibitors of human renin[J].Chem Biol,2000,7:493-504.
  • 9[9]Dieterle W,Corynen S,Mann J.Effects of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects[J].Br J Clin Pharmacol,2004,58:433-436.
  • 10[10]Nussberger J,Wuerzner G,Jensen C,et al.AngiotensinⅡ suppression in humans by the orally active renin inhibitor aliskiren (SPP 100).Comparison with enalapril[J].Hypertension,2002,39:e1-8.

同被引文献18

  • 1Parring HH, Persson F, Lewis JB, et al. The combination of aliskiren, a direct renin inhibitor, and losartan in patients with type 2 diabetes and nephropathy[J]. New Engl J Med, 2008,358(23) :2433-2446.
  • 2McMurray JJV, Pitt B, Latini R, et al, Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure [J]. Circ Heart Fail,2008,1(1) : 17-24.
  • 3Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the di rect renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy[J]. Circulation, 2009,119 (4) :530-537.
  • 4Jordan J, Engeli S, Boye SW, et al. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension[J]. Hyper tension,2007,49(5) :1047-1055.
  • 5Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension[J]. J Renin Angiotensin Aldosterone Syst,2007,8(4) : 190-198.
  • 6Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: subanalysis of a 52-week, randomized, double-blind trial[J]. J Hypertens,2009,27(7) : 1493-1501.
  • 7Oh BH, Mitchell J, Herron JER, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension[J]. J Am Coll Cardiol,2007,49(11) : 1157-1163.
  • 8Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihy- pertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide[J]. Circulation, 2009,27,119 (3): 417- 425.
  • 9Andersen K, Weinberger M H, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial[J]. J Hypertens, 2008,26 (3) : 589-599.
  • 10Oparil S, Yarrows, S, Patel S, et al. Efficacy and safety of corn bined use of aliskiren and valsartan in patients with hypertension a randomised, double-blind trial[J]. Lancet, 2007,370 (9583) : 221 229.

引证文献1

二级引证文献2

中华高血压杂志
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部